ACR Convergence

The 2024 Dubois Memorial Lecture focused on health inequities with lupus & strategies to close the gap.

The goal is to identify people at risk for RA &, perhaps, prevent its onset.

The session highlighted the importance of correctly identifying and treating patients with RA-ILD early in their disease course.

Experts offered perspectives on how symptoms of rheumatic disease, such as fatigue, affect the physical, cognitive and emotional health of patients and offered solutions.

At ACR Convergence 2024, the ACR honored clinical and research fellows in programs from New York to California and points between.

The 2024 ACR Awards of Distinction honor members for their outstanding contributions to the field of rheumatology.

Rheumatic diseases are intrinsically linked to environmental conditions. With a constantly changing environment, how can rheumatologists adapt to the challenges of global climate change, pollution and other environmental threats? The Environment + Genetics Tamiko Katsumoto, MD, a clinical associate professor in the Division of Immunology and Rheumatology at Stanford University, Palo Alto, Calif.,  emphasizes the…

WASHINGTON, D.C.—The workforce shortage in rheumatology is a looming crisis that demands immediate attention. The ACR’s 2015 Workforce Study projected that by 2030, the supply of adult rheumatologists would dwindle by 31%, in contrast to the increase in demand by close to 138%.1 The situation is even worse for pediatric rheumatology and in rural and…

WASHINGTON, D.C.—As of November 2024, there are 16 biologic disease-modifying anti-rheumatic drugs (bDMARDs) that are FDA approved for the treatment of psoriatic arthritis (PsA). Incredible news, right? But as my fellowship program director used to say, “There’s no free lunch.” This buffet of options is excellent for our patients, but poses challenges to the practicing…

Background/Purpose Psoriasis and psoriatic arthritis (PsA) are closely linked inflammatory conditions that can affect both children and adults. In children, these diseases are associated with traditional cardiovascular disease risk factors and subclinical atherosclerosis. In older adults, systemic inflammation from psoriasis and PsA accelerates atherosclerosis, and these conditions are independent risk factors for severe cardiovascular disease…